Moderna Inc [MRNA] stock prices are up 1.41% to $99.48 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MRNA shares have gain 7.85% over the last week, with a monthly amount drifted -0.55%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024. In a post published today on Yahoo Finance, Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth annual Investor Event focused on vaccines and business updates on Wednesday, March 27, 2024. The presentation will begin at 9:00 a.m. ET.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on February 26, 2024, when HSBC Securities downgraded its rating to a Reduce and also boosted its price target to $86 from $75. Previously, Oppenheimer upgraded its rating to Outperform on January 02, 2024, and kept the price target unchanged to $142. On November 29, 2023, Canaccord Genuity initiated with a Hold rating and assigned a price target of $82 on the stock. HSBC Securities upgraded its rating to a Hold and decreased its price target to $69 on November 03, 2023. Deutsche Bank downgraded its rating to a Sell and reduced its price target to $60 on November 02, 2023. TD Cowen downgraded its rating to Market Perform for this stock on August 04, 2023, and downed its price target to $125. In a note dated August 03, 2023, Deutsche Bank downgraded an Hold rating on this stock but restated the target price of $125.
The stock price of Moderna Inc [MRNA] has been fluctuating between $62.55 and $163.24 over the past year. Currently, Wall Street analysts expect the stock to reach $176.8 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $99.48 at the most recent close of the market. An investor can expect a potential return of 77.72% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
The Moderna Inc [NASDAQ:MRNA] reported sales of 6.86B for trailing twelve months, representing a drop of -44.05%. Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -0.62%, Pretax Profit Margin comes in at -0.58%, and Net Profit Margin reading is -0.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.3 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 97.36 points at the first support level, and at 95.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 100.76, and for the 2nd resistance point, it is at 102.04.
Moderna Inc [MRNA] reported earnings per share of $0.55 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.97/share, meaning a difference of $1.52 and a surprise factor of 156.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$9.53 per share as compared to estimates of -$1.93 per share, a difference of -$7.6 representing a surprise of -393.80%.
Ratios To Look Out For
It’s worth pointing out that Moderna Inc [NASDAQ:MRNA]’s Current Ratio is 3.42. Also, the Quick Ratio is 3.36, while the Cash Ratio stands at 0.96. Considering the valuation of this stock, the price to sales ratio is 5.54, the price to book ratio is 2.74.
Transactions by insiders
Recent insider trading involved Hoge Stephen, President, that happened on Mar 04 ’24 when 309.0 shares were sold. Chief Legal Officer, Klinger Shannon Thyme completed a deal on Mar 04 ’24 to sell 117.0 shares. Meanwhile, President Hoge Stephen sold 2388.0 shares on Feb 29 ’24.
